C&G Editor in Chief, Erin Harris

  1. CGT’s Top Regulatory Challenges Broken Down By Segment 1/31/2023

    Our recent Cell & Gene Live, Tackling Cell & Gene Therapies’ Top 3 Regulatory Impediments, featuring BridgeBio's Dr. Adora Ndu and REGENXBIO's Dr. Nina Hunter, delivered just under 60 minutes of exceptionally valuable information. We also know that your time is likely not your own, which is why we’ve broken down the full-length version into digestible segments that you can view on your own time.

  2. XyloCor’s Phase 2 EXACT Trial Success 1/31/2023

    XyloCor Therapeutics’ CEO, Albert Gianchetti provides updates about the clinical-stage biopharma’s EXACT clinical trial.

  3. Astellas Pharma: Moving On from Clinical Hold 1/26/2023

    Ha Tran, Executive Medical Director at Astellas Pharma, explains the cause of the clinical hold and the future of the program now that the hold has been lifted.

  4. Atara Biotherapeutics, Kite, and Tmunity 1/17/2023

    Inside the recent news out of Atara Biotherapeutics' allo approval and Kite's acquisition of Tmunity Therapeutics.

  5. Tackling CGT’s Top 3 Regulatory Impediments 12/29/2022

    2022 brought a great deal of change and disruption to cell and gene therapy companies. The news of companies closing their pipelines, undergoing liquidations, etc. was loud this year. The reasons for these pitfalls are varied and sundry, but despite the noise, cell and gene therapies have made impressive clinical progress. But the sector continues to face big hurdles, and overcoming regulatory challenges is one of them.

  6. My Top Editorial Picks for 2022 12/19/2022

    Fair warning, Cell & Gene readers. While this list includes some of my favorite editorial from 2022, it’s not even remotely close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article. Here are some highlights that helped to inform our readers about everything from process development to vendor selection to partnering with the right investment team.

  7. How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 2) 12/9/2022

    In the final part of the series, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio explain how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.

  8. How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 1) 12/8/2022

    In part one of this two-part series, as seen in Life Science Leader magazine, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio weigh in on the understanding of how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.

  9. CGT In 2023 With Cartesian Therapeutics, Poseida Therapeutics, REGENXBIO, And Spark Therapeutics 11/29/2022

    To better understand 2023’s most pressing issues in the cell and gene therapy space, I sought expert commentary from Cartesian Therapeutics’ Murat Kalayoglu, Poseida Therapeutics’ Mark Gergen, REGENXBIO’s Nina Hunter, and Spark Therapeutics’ Ron Philip.

  10. DTx Pharma And The Near-Term Future Of RNA Therapeutics 11/21/2022

    To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, I caught up with DTx Pharma's CEO Arthur Suckow.